Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-03-2015 | Original Article – Clinical Oncology

Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer

Authors: Marta Scorsetti, Tiziana Comito, Angelo Tozzi, Pierina Navarria, Antonella Fogliata, Elena Clerici, Pietro Mancosu, Giacomo Reggiori, Lorenza Rimassa, Guido Torzilli, Stefano Tomatis, Armando Santoro, Luca Cozzi

Published in: Journal of Cancer Research and Clinical Oncology | Issue 3/2015

Abstract

Purpose

To evaluate the feasibility and efficacy of stereotactic body radiation therapy (SBRT) in the treatment of colorectal liver metastases.

Methods

Forty-two patients with inoperable colorectal liver metastases not amenable to radiofrequency ablation (RFA) were treated with SBRT for a total number of 52 lesions. All patients received a total dose of 75 Gy in 3 consecutive fractions. Mean size of the lesions was 3.5 cm (range 1.1–5.4). Toxicity was classified according to the Common Toxicity Criteria version 3.0.

Results

Median follow-up was 24 (range 4–47) months. The progression in field was observed in 5 lesions. Twenty-four months actuarial local control (LC) rate was 91 %. Median overall survival (OS) was 29.2 ± 3.7 months. Actuarial OS rate at 24 months was 65 %. Median progression-free survival was 12.0 ± 4.2 months; 24 months actuarial rate was 35 %. No patients experienced radiation-induced liver disease or grade ≥3 toxicity.

Conclusions

SBRT represents a feasible alternative for the treatment of colorectal liver metastases not amenable to surgery or other ablative treatments in selected patients, showing optimal LC and promising survival rate.

Adam R, Wicherts DA, De Haas RJ et al (2009) Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 27:1829–1835CrossRefPubMed

Adam R, De Gramont A, Figueras R et al (2012) The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist 17:1225–1239CrossRefPubMedCentralPubMed

Alongi F, Arcangeli S, Filippi AR, Ricardi U, Scorsetti M (2012) Review and uses of stereotactic body radiation therapy for oligometastases Oncologist 17:1100–1107

Ambrosino G, Polistina F, Costantin G et al (2009) Image-guided robotic stereotactic radiosurgery for unresectable liver metastases: preliminary results. Anticancer Res 29:3381–3384PubMed

Biasco G, Derenzini E, Grazi G, Ercolani G, Ravaioli M, Pantaleo M, Brandi G (2006) Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties. Cancer Treat Rev 32:214–228CrossRefPubMed

Bozzetti F, Cozzaglio L, Boracchi P, Marubini E, Doci R, Bignami P, Gennari L (1993) Comparing surgical resection of limited hepatic metastases from colorectal cancer to non-operative treatment. Eur J Surg Oncol 19:162–167PubMed

Chang D, Swaminath A, Kozak M et al (2011) Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer 117:4060–4069CrossRefPubMed

Cirocchi R, Trastulli S, Boselli C et al (2012) Radiofrequency ablation in the treatment of liver metastases from colorectal cancer. Cochrane Database Syst Rev 6:CD006317PubMed

Clancy C, Burke J, Barry M, Kalady M, Coffey J (2014) A meta-analysis to determine the effect of primary tumor resection for stage IV colorectal cancer with unresectable metastases on patient survival. Ann Surg Oncol. doi:10.1245/s10434-014-3805-4 PubMed

Corbin K, Hellman S, Weichselbaum R (2013) Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy. J Clin Oncol 31:1384–1390CrossRefPubMed

Dawson LA, Lawrence TS (2004) The role of radiotherapy in the treatment of liver metastases. Cancer 10:139–144CrossRef

Dawson LA, Normolle D, Balter JM et al (2002) Analysis of radiation induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 53:810–821CrossRefPubMed

Demaria S, Formenti S (2012) Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front Oncol 2:153PubMedCentralPubMed

Eisenhauer E, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefPubMed

Eriguchi T, Takeda A, Sanuki N et al (2013) Acceptable toxicity after stereotactic body radiation therapy for liver tumors adjacent to the central biliary system. Int J Radiat Oncol Biol Phys 85:1006–1011CrossRefPubMed

Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C et al (2013) GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. International Agency for Research on Cancer, Lyon, France. http://globocan.iarc.fr

Fong Y, Fortner J, Sun RL et al (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309–318CrossRefPubMedCentralPubMed

Gillams A, Lees W (2009) Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol 19:1206–1213CrossRefPubMed

Goodman KA, Wiegner EA, Maturen KE et al (2010) Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys 78:486–493CrossRefPubMed

Herfarth KK, Debus J (2005) Stereotactic radiation therapy for liver metastases. Chirurg 76:564–569CrossRefPubMed

Hoyer M, Roed H, Traberg HA et al (2006) Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol 45:823–830CrossRefPubMed

Katz AW, Carey-Sampson M, Muhs AG, Milano MT, Schell MC, Okunieff P (2007) Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. Int J Radiat Oncol Biol Phys 67:793–798CrossRefPubMed

Kavanagh BD, Bradley JD, Timmerman RD (2008) Stereotactic irradiation of tumors outside the central nervous system. In: Halperin EC, Perez CA, Brady LW (eds) Perez and Brady’s principles and practice of radiation oncology, 5th edn. Lippincott, Williams and Wilkins, Baltimore, pp 389–390

Lee MT, Kim JJ, Dinniwell R et al (2009) Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 27:1585–1591CrossRefPubMed

Leonard G, Brenner B, Kemeny N (2005) Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 23:2038–2048CrossRefPubMed

Quan D, Gallinger S, Nhan C, On behalf of the Surgical Oncology Program at Cancer Care Ontario et al (2012) The role of liver resection for colorectal cancer metastases in an era of multimodality treatment: a systematic review. Surgery 151:860–870CrossRefPubMed

Rule W, Timmerman R, Abdulrahman R et al (2011) Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases. Ann Surg Oncol 18:1081–1087CrossRefPubMed

Rusthoven KE, Kavanagh BD, Cardenes H et al (2009) Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 27:1572–1578CrossRefPubMed

Saltz LB (2005) Metastatic colorectal cancer: is there one standard approach? Oncology (Williston Park) 19:1147–1154

Scheele J, Stangl R, Altendorf-Hofmann A (1990) Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 77:1241–1246CrossRefPubMed

Scorsetti M, Arcangeli S, Tozzi A et al (2013) Is stereotactic body radiation therapy an attractive option for unresectable liver metastasis? A preliminary report from a phase 2 trial. Int J Radiat Oncol Biol Phys 86:336–342 CrossRefPubMed

Siperstein A, Berber E, Ballem N, Parikh R (2007) Survival after radiofrequency ablation of colorectal liver metastases. 10-year experience. Ann Surg 246:559–567CrossRefPubMed

Timmerman R, Papiez L, McGarry R et al (2003) Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 124:1946–1955CrossRefPubMed

Tomlinson J, Jarnagin W, Dematteo R et al (2007) Actual 10-year survival after resection of 514 colorectal liver metastases defines cure. J Clin Oncol 25:4575–4580CrossRefPubMed

van der Pool A, Mendez Romero A, Wunderink W et al (2010) Stereotactic body radiation therapy for colorectal liver metastases. Br J Surg 97:377–382CrossRefPubMed

Yoon S, Tanabe K (1999) Surgical treatment and other regional treatments for colorectal cancer liver metastases. Oncologist 4:197–208PubMed

Title: Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer
Authors: Marta Scorsetti
Tiziana Comito
Angelo Tozzi
Pierina Navarria
Antonella Fogliata
Elena Clerici
Pietro Mancosu
Giacomo Reggiori
Lorenza Rimassa
Guido Torzilli
Stefano Tomatis
Armando Santoro
Luca Cozzi
Publication date: 01-03-2015
Publisher: Springer Berlin Heidelberg
Published in: Journal of Cancer Research and Clinical Oncology / Issue 3/2015
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-014-1833-x

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2015

Alzheimer disease and cancer risk: a meta-analysis

Targeting VEGF and interleukin-6 for controlling malignant effusion of primary effusion lymphoma

Ezrin-expressing lung adenocarcinoma cells and podoplanin-positive fibroblasts form a malignant microenvironment

Serum peptide signatures for pancreatic cancer based on mass spectrometry: a comparison to CA19-9 levels and routine imaging techniques

Comparison of Glasgow prognostic score and prognostic index in patients with advanced non-small cell lung cancer

ZNF695 methylation predicts a response of esophageal squamous cell carcinoma to definitive chemoradiotherapy

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page